The Asia-Pacific region is seeing rapid growth in oncology drug research, with a 138 percent increase in clinical trial activity from 2010 to 2020, according to a recent Clinical Trials Arena report. The APAC region now ranks first in the world for the number of ongoing oncology clinical trials, accounting for more than half of those studies.
Large populations, a favorable regulatory climate, and a high incidence of cancer are among the many reasons sponsors are drawn to the region.
In this webinar, we will examine the advantages of conducting trials in this fast-growing region and explore other issues sponsors should consider when choosing sites for upcoming trials.
• Patient access
• Cost advantages
• Regulatory landscape
• The digital revolution
Rupa Doshi, Ph.D,
Vice President, Strategy, Oncology Strategy, Premier Research
With more than 23 years in the industry, Dr. Doshi is an experienced professional with demonstrated leadership skills in clinical operations, global project/program management, customer management and strategy development. Her experience spans the clinical development spectrum from pre-IND to NDA and she has also led global teams in the execution of full-service complex clinical trials across all phases.
Dr. Doshi brings drug discovery and clinical development experience with biologics, small molecules as well as cell and gene therapy products over a range of indications. Her doctoral research focus was on breast cancer, her post-doctoral research was in site-directed mutagenesis and she holds patents in the area of angiogenesis. Dr. Doshi has also supported three products resulting in agency approval.